On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing ...
July 7 (Reuters) - Obesity-focused clinical-stage biotechnology company Kalohexis on Tuesday confidentially filed to go public in the U.S., adding to an activity rebound in the initial public offering ...
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout ...
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...
Vertex will acquire Crinetics Pharmaceuticals for $10 billion, its largest deal yet, adding an approved rare-disease drug to ...
Following an independent salary analysis, this landmark certification sets a benchmark for data-driven pay equity and ...
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...
Biotechnology investors often focus on clinical milestones, regulatory approvals, and commercial launches. Yet in antibody ...
Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results